Toggle Contrast

Analysing medicine usage data and quantifying the costs associated with unwarranted variation

The QuintilesIMS project, in partnership with the NHS, the pharmaceutical company Merck and uMotif, seeks to identify ways of using NHS resources more efficiently within the secondary care setting, improve quality, reduce unwarranted variation in the delivery of care and establish a more accurate understanding of the patient experience during their treatment, placing a particular focus on colorectal cancer – one of the most common cancers in Britain and the second leading cause of cancer-related deaths.

By quantifying the costs associated with the identified unwarranted variation this new insight will enable the Trusts to optimise their use of medicines, spending money where it matters most to deliver better patient outcomes.

The project will use innovative technology, provided by uMotif, to uniquely capture patient symptom, outcome, experience and wearable device data throughout their treatment, so that our understanding of the patient’s treatment journey is central to the analysis.